Edition:
United States

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
12:33pm EST
Change (% chg)

$0.01 (+0.62%)
Prev Close
$1.61
Open
$1.69
Day's High
$1.69
Day's Low
$1.56
Volume
13,543
Avg. Vol
21,951
52-wk High
$6.50
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Soleno Therapeutics Announces $15 Million Private Placement
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT.SOLENO THERAPEUTICS INC - SOLENO TO SELL 8.1 MILLION OF ITS COMMON SHARES AT $1.8425/SHARE.SOLENO THERAPEUTICS - TO USE PROCEEDS CONDUCT PLANNED PHASE III PROGRAM OF DIAZOXIDE CHOLINE CONTROLLED-RELEASE IN PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology
Friday, 8 Dec 2017 08:00am EST 

Dec 8 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, OAHL WILL INVEST UP TO $2.2 MILLION IN TRANCHES TO PURCHASE SHARES OF OUR CAPNIA SUBSIDIARY.SOLENO THERAPEUTICS INC - CAPNIA WILL NO LONGER BE A WHOLLY-OWNED SUBSIDIARY OF SOLENO.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, GOING FORWARD, OAHL WILL BE RESPONSIBLE FOR FUNDING OPERATIONS OF CAPNIA.  Full Article

Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.24 from continuing operations.Q3 loss per share $0.35.  Full Article

Soleno Therapeutics announces 1-for-5 reverse stock split
Thursday, 5 Oct 2017 01:00pm EDT 

Oct 5 (Reuters) - Soleno Therapeutics Inc ::Soleno Therapeutics announces 1-for-5 reverse stock split.Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017.  Full Article

Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome
Friday, 15 Sep 2017 08:00am EDT 

Sept 15 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome.Soleno Therapeutics Inc - phase iii study expected to begin by end of 2017.  Full Article

Soleno Therapeutics CFO David O’Toole to transition from Soleno in mid-Sept ‍​
Tuesday, 5 Sep 2017 05:08pm EDT 

Sept 6 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics Inc says David O’Toole, company’s chief financial officer, will transition from Soleno in mid-September - SEC filing ‍​.Says Jonathan R. Wolter appointed interim CFO.  Full Article

Soleno Therapeutics Q2 loss per share $0.07
Friday, 11 Aug 2017 04:05pm EDT 

Aug 11 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results.Q2 loss per share $0.06 from continuing operations.Q2 loss per share $0.07.Soleno Therapeutics Inc - ‍preparing to begin phase III program by end of year​.  Full Article

Soleno Therapeutics reports Q2 loss/share of $0.07
Friday, 11 Aug 2017 04:05pm EDT 

Aug 11 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results.Soleno - To begin phase iii program by end of year for DCCR in Prader-Willi Syndrome ​.Q2 loss per share $0.06 from continuing operations.Q2 loss per share $0.07.  Full Article

Soleno Therapeutics announces sale of non-strategic assets to Flexicare Inc
Monday, 24 Jul 2017 04:05pm EDT 

July 24 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics announces sale of non-strategic assets to Flexicare, Inc..Soleno Therapeutics Inc - ‍expect to initiate a phase III clinical trial for DCCR by end of 2017​.Soleno Therapeutics Inc- ‍we expect to initiate a phase III clinical trial for DCCR by end of 2017​.  Full Article

Soleno Therapeutics announces completion of FDA meeting for DCCR in Prader-Willi syndrome
Wednesday, 5 Jul 2017 08:00am EDT 

July 5 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics announces successful completion of FDA meeting for DCCR in Prader-Willi syndrome.Soleno Therapeutics Inc says positive guidance received on key elements of phase III program.Soleno Therapeutics Inc says expects to initiate pivotal phase III clinical trial by year-end 2017.Soleno Therapeutics -FDA expressed support for change in hyperphagia score, without a change in weight, compared to placebo as primary endpoint for study.  Full Article